The stock of Caribou Biosciences Inc (CRBU) has gone up by 7.69% for the week, with a -16.13% drop in the past month and a -49.60% drop in the past quarter. The volatility ratio for the week is 15.59%, and the volatility levels for the past 30 days are 11.06% for CRBU. The simple moving average for the past 20 days is -8.41% for CRBU’s stock, with a -52.77% simple moving average for the past 200 days.
Is It Worth Investing in Caribou Biosciences Inc (NASDAQ: CRBU) Right Now?
Moreover, the 36-month beta value for CRBU is 2.28. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CRBU is 80.81M and currently, short sellers hold a 12.23% of that float. On April 11, 2025, CRBU’s average trading volume was 1.20M shares.
CRBU) stock’s latest price update
The stock of Caribou Biosciences Inc (NASDAQ: CRBU) has decreased by -3.84 when compared to last closing price of 0.86. Despite this, the company has experienced a 7.69% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-10 that NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. (“Caribou” or “the Company”) (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CRBU.
Analysts’ Opinion of CRBU
Many brokerage firms have already submitted their reports for CRBU stocks, with Evercore ISI repeating the rating for CRBU by listing it as a “In-line.” The predicted price for CRBU in the upcoming period, according to Evercore ISI is $3 based on the research report published on June 03, 2024 of the previous year 2024.
Evercore ISI gave a rating of “Outperform” to CRBU, setting the target price at $13 in the report published on October 31st of the previous year.
CRBU Trading at -25.54% from the 50-Day Moving Average
After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.30% of loss for the given period.
Volatility was left at 11.06%, however, over the last 30 days, the volatility rate increased by 15.59%, as shares sank -12.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.34% lower at present.
During the last 5 trading sessions, CRBU rose by +15.49%, which changed the moving average for the period of 200-days by -49.64% in comparison to the 20-day moving average, which settled at $0.9054. In addition, Caribou Biosciences Inc saw -48.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRBU starting from Haurwitz Rachel E., who purchase 20,000 shares at the price of $1.02 back on Mar 14 ’25. After this action, Haurwitz Rachel E. now owns 3,369,395 shares of Caribou Biosciences Inc, valued at $20,400 using the latest closing price.
MCCLUNG BARBARA G, the Chief Legal Officer of Caribou Biosciences Inc, sale 3,564 shares at $1.35 during a trade that took place back on Feb 21 ’25, which means that MCCLUNG BARBARA G is holding 443,502 shares at $4,811 based on the most recent closing price.
Stock Fundamentals for CRBU
Current profitability levels for the company are sitting at:
- -16.67 for the present operating margin
- 0.84 for the gross margin
The net margin for Caribou Biosciences Inc stands at -14.92. The total capital return value is set at -0.59. Equity return is now at value -47.99, with -39.14 for asset returns.
Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.22.
Currently, EBITDA for the company is -166.62 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 8.79. The receivables turnover for the company is 3.07for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.16.
Conclusion
To wrap up, the performance of Caribou Biosciences Inc (CRBU) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
